News

Boehringer Ingelheim recently released a report on the company’s findings from the Phase IIIb OTEMTO 1 (NCT01964352) & 2 (NCT02006732) clinical trials, which are testing combination treatment Spiolto® Respimat® (tiotropium/olodaterol) for patients with chronic obstructive pulmonary disease (COPD). The update is published in the…

A study recently published in the journal Oxidative Medicine and Cellular Longevity reviewed the link between reactive oxygen species (ROS), stem cell aging and lung disorders like chronic obstructive pulmonary disease (COPD). The study is titled “Reactive Oxygen Species in Mesenchymal Stem Cell Aging:…

Boehringer Ingelheim recently announced the completion of the phase IIIb OTEMTO® 1 & 2 trials for their pipeline drug STIOLTO RESPIMAT, and have published the study data online in the Respiratory Medicine journal.  The new data reveals that the drug has the potential to improve clinical outcomes in patients with…

Care co-ordination among patients with Chronic Obstructive Pulmonary Disorder (COPD) is one of the most important goals in maintaining patient health as far as primary care is concerned. COPD is the third leading cause of death in the United States, with an overall economic burden of approximately $50 billion, most…

In a report published in the journal Proceedings of the National Academy of Sciences, a team of experts from the Johns Hopkins University Department of Chemical and Biomolecular Engineering, Johns Hopkins University School of Medicine and the Federal University of Rio de Janeiro in Brazil demonstrate their…

In a new study entitled “Association of psychological disorders with 30–day readmission rates in patients with Chronic Obstructive Pulmonary Disease,” authors at The University of Texas Medical Branch (UTMB) investigated if psychological disorders such as depression, anxiety or alcohol abuse are associated with an increase in…

Entra Health has recently announced the launch of Entra360, a novel solution for easily and effectively implementing wireless biometric data. Entra360 is a particularly innovative solution for both the payer or provider, as well as the COPD clinical research market. Entra360 is one of several efforts the company is making to provide easy-to-implement solutions to allow remote…

Cipla, an Indian multinational pharmaceutical and biotechnology company, recently presented a new respiratory inhaler called Synchrobreathe (SB) at the South Africa Thoracic Society (SATS) Annual Conference that took place in Cape Town, South Africa between the 7h and the 10th of August. The company will soon launch the innovative inhaler,…

The ACI Association recently compiled a report on Aquinox Pharmaceuticals Inc. based on the company’s internal reports to make them available to the general public. Aquinox is currently developing AQX-1125, an investigational therapy for COPD, which was recently evaluated in a phase 2 clinical trial called FLAGSHIP. Aquinox announced recently that its FLAGSHIP…

Researchers at Ben-Gurion University of the Negev and Soroka University Medical Center in Israel recently published in the journal CHEST the finding that patients with chronic obstructive pulmonary disease (COPD) who were hospitalized due to exacerbations related to the disease and who did not attend…